linagliptin: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
linagliptin: clinical details
Prescribing considerations
- Confirm adult type 2 diabetes and use alongside diet and exercise.
- Assess hypoglycaemia risk when insulin or a sulphonylurea is co-prescribed.
- Review any history of pancreatitis and counsel about characteristic symptoms.
- Clinical experience in hepatic impairment is limited despite pharmacokinetic data suggesting little effect on exposure.
- Efficacy was not established in children and adolescents in the cited product information.
Contraindications and cautions
- Hypersensitivity to linagliptin or any tablet excipient.
- Do not use for type 1 diabetes or diabetic ketoacidosis.
- Avoid restarting if acute pancreatitis is confirmed.
Monitoring
- Use HbA1c and routine diabetes reviews to assess effectiveness and ongoing suitability.
- Monitor for hypoglycaemia when combined with insulin or a sulphonylurea.
- Investigate persistent severe abdominal pain promptly and discontinue if pancreatitis is suspected.
- Assess blistering skin lesions for bullous pemphigoid and discontinue if suspected.
Clinical pharmacology
Linagliptin is a selective, reversible DPP-4 inhibitor. Metabolism and urinary elimination play minor roles; most administered material is eliminated through the faecal route. It has low potential to alter the pharmacokinetics of many commonly co-prescribed medicines.
Formulation and product differences
- The selected product is a single-ingredient, light-red, round film-coated tablet.
- Fixed-dose products combining linagliptin with other glucose-lowering agents are separate preparations with different product information.
linagliptin preparations and strengths
Tablet
Route: Oral
Strengths: 5 mg
linagliptin interactions
Linagliptin has relatively low interaction potential, but some combinations require attention.
Insulin and sulphonylureas, such as gliclazide
The combination increases the risk of hypoglycaemia, so glucose control and symptoms require closer review.
Rifampicin
It can reduce linagliptin exposure and may weaken its glucose-lowering effect, particularly with prolonged use.
Carbamazepine, phenytoin and phenobarbital
These strong enzyme and transporter inducers may reduce linagliptin effectiveness; direct combination studies are limited.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.